Alice, Éloi, Magali and Robert: the lives of four patients with psoriasis and the therapeutic approaches of eight European experts

British Journal of Dermatology

Volumn 161, Issue SUPPL. 2, 2009, Pages 1-30

  Dubertret, L ^a   Chimenti, S ^b   Christophers, E ^c   Dauden E ^d   De Rie, M ^e   Kragballe, K ^g   Griffiths, C E M ^f   Stahle M ^h   Stingl, G ⁱ  

^a Department of Dermatology Hôapital ^*  (France)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

^h KAROLINSKA INSTITUTE   (Sweden)

ⁱ UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETAMETHASONE; BETAMETHASONE DIPROPIONATE; BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL; CLOBETASOL; CLOBETASOL PROPIONATE; CORTICOSTEROID; CYCLOSPORIN A; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMADERM; INFLIXIMAB; ISONIAZID; LIDOCAINE; METHOTREXATE; METHYLPREDNISOLONE; MOMETASONE FUROATE; PIMECROLIMUS; PRILOCAINE; PSORALEN; PYRIDOXINE; TACROLIMUS; TAZAROTENE; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VITAMIN D DERIVATIVE; DERMATOLOGICAL AGENT;

ACUTE PANCREATITIS; ALLERGIC REACTION; ANTIBIOTIC PROPHYLAXIS; BALNEOTHERAPY; BLOOD PRESSURE MONITORING; CASE STUDY; CHEILITIS; CHILDHOOD DISEASE; COMORBIDITY; CONGENITAL MALFORMATION; DEPRESSION; DESQUAMATION; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY NOSE; EMBRYOTOXICITY; EMOTIONAL STRESS; EUROPE; EVENING DOSAGE; FATIGUE; FATTY LIVER; FETUS WASTAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERTENSION; HYPERTRICHOSIS; INFECTION; INJECTION SITE BLEEDING; IRRITABILITY; IRRITANT DERMATITIS; KIDNEY DISEASE; LEUKOPENIA; LIBIDO; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; LIVER TOXICITY; LOW DRUG DOSE; LUNG TUBERCULOSIS; LUPUS LIKE SYNDROME; MALE FERTILITY; MORNING DOSAGE; MOUTH ULCER; MUSCULOSKELETAL STIFFNESS; NAIL PSORIASIS; NARROWBAND ULTRAVIOLET B RADIATION; NAUSEA; NEPHROTOXICITY; NONHUMAN; OCCLUSIVE DRESSING; OSTEOPOROSIS; PAIN; PARESTHESIA; PHOTOTHERAPY; POSTPRIMARY TUBERCULOSIS; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; PSORIASIS GUTTATA; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUSTULAR PSORIASIS; PUVA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SCALP PSORIASIS; SIDE EFFECT; SKIN ATROPHY; SKIN CANCER; SKIN IRRITATION; SKIN PIGMENTATION; SPONTANEOUS ABORTION; STRIA; TELANGIECTASIA; TERATOGENESIS; TERATOGENICITY; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL; ULTRAVIOLET B RADIATION; ADULT; CASE REPORT; CHILD; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; FEMALE; MALE; MIDDLE AGED; PROFESSIONAL PRACTICE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADULT; CHILD; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROFESSIONAL PRACTICE; PSORIASIS; YOUNG ADULT;

EID: 67650469273     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09173.x     Document Type: Review

References (114)

1. Abell E, Samman PD. Intradermal triamcinolone treatment of nail dystrophies. Br J Dermatol 1973 89 : 191 7.
2. Bleeker JJ. Intralesional triamcinolone acetonide using the Port-O-Jet and needle injections in localized dermatoses. Br J Dermatol 1974 91 : 97 101.
3. Peachey RD, Pye RJ, Harman RR. The treatment of psoriatic nail dystrophy with intradermal steroid injections. Br J Dermatol 1976 95 : 75 8.
4. de Berker DA, Lawrence CM. A simplified protocol of steroid injection for psoriatic nail dystrophy. Br J Dermatol 1998 138 : 90 5.
5. Sánchez-Regaña M, Umbert P. Aspectos diagnósticos y terapeúticos de la psoriasis ungueal. Actas Dermosifiliogr 2008 99 : 34 43. (Pubitemid 351239803)
6. de Berker D. Management of nail psoriasis. Clin Exp Dermatol 2000 25 : 357 62.
7. Lebwohl M, Menter A, Koo J et al. Case studies in severe psoriasis: a clinical strategy. J Dermatolog Treat 2003 14 (Suppl. 2 26 46. (Pubitemid 37474604)
8. Scher R, Daniel C. Nails: Therapy, Diagnosis, Surgery. Philadelphia : W.B. Saunders Company, 2003.
9. Gupta AK, Lynde CW, Jain HC et al. A higher prevalence of onychomycosis in psoriatics compared with non-psoriatics: a multicentre study. Br J Dermatol 1997 136 : 786 9.
10. Baran RL, Tosti A. Topical treatment of nail psoriasis with a new corticoid-containing nail lacquer formulation. J Dermatol Treat 1999 10 : 201 4.
11. Sánchez Regaña M, Martín G, Umbert P et al. Treatment of nail psoriasis with 8% clobetasol nail lacquer: positive experience in 10 patients. J Eur Acad Dermatol Venereol 2005 19 : 573 7.
12. Tosti A, Piraccini BM, Cameli N et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998 139 : 655 9.
13. Rigopoulos D, Ioannides D, Prastitis N et al. Nail psoriasis: a combined treatment using calcipotriol cream and clobetasol propionate cream. Acta Derm Venereol 2002 82 : 140. (Pubitemid 34596692)
14. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007 20 : 60 7.
15. Dunna S, Finlay A. Psoriasis: improvement during and worsening after pregnancy. Br J Dermatol 1989 120 : 584. (Pubitemid 19101186)
16. Dupuy P, Geiger J. Psoriasis and pregnancy. In : Psoriasis (Dubertret L, ed). Brescia : ISED, 1994 261 4.
17. Farber E, Nall M. The natural history of psoriasis in 5,600 patients. Dermatologica 1974 148 : 1 18.
18. Schalla W, Bauer E, Schaefer H. Skin permeability of anthralin. Br J Dermatol 1981 105 : 104 8.
19. Edmonds E, Morris S, Short K et al. Pustular psoriasis of pregnancy treated with ciclosporin and high-dose prednisolone. Clin Exp Dermatol 2005 30 : 709 10.
20. Finch T, Tan C. Pustular psoriasis exacerbated by pregnancy and controlled by cyclosporin A. Br J Dermatol 2000 142 : 582 4.
21. Harvima R, Laukkanen A, Haring P et al. Generalized pustular psoriasis during pregnancy: an effective treatment with cyclosporin. Duodecim 1999 115 : 391 5.
22. Lammer E. Embryopathy in infant conceived one year after termination of maternal etretinate. Lancet 1988 2 : 1080 1.
23. Hyrich K, Symmons D, Watson K et al. Pregnancy outcome in women who were exposed to anti-tumor necrosis factor agents: results from a national population register. Arthritis Rheum 2006 54 : 2701 2.
24. Joven B, Garcia-Gonzalez A, Ruiz T et al. Pregnancy in women receiving anti-TNF-alpha therapy, experience in Spain. Arthritis Rheum 2005 52 : S349.
25. Chambers C, Johnson D, Jones K. Pregnancy outcomes in women exposed to etanercept: The OTIS autoimmune diseases in pregnancy project. J Am Acad Dermatol 2007 56 : AB10 (abstract).
26. Katz J, Antoni C, Keenan G et al. Outcome of pregnancy in patients receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004 99 : 2385 92.
27. Lichtenstein G, Cohen R, Feagan B et al. Safety of infliximab in Crohn's disease: data from the 5000-patient TREAT Registry. In : Digestive Disease Week 2004. New Orleans, LA : 2004. Abstract 102194.
28. Mahadevan U, Kane S, Sandborn W et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005 21 : 733 8.
29. Sills E, Perloe M, Tucker M et al. Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. Am J Reprod Immunol 2001 46 : 366 8.
30. Chakravarty E, Sanchez-Yamamoto D, Bush T. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy. J Rheumatol 2003 30 : 241 6.
31. Carter J, Valeriano J, Vasey F. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship? J Rheumatol 2006 33 : 1014 17.
32. Roux C, Brocq O, Breuil V et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)-alpha therapy. Rheumatology (Oxford) 2007 46 : 695 8.
33. Coburn L, Wise P, Schwartz D. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006 51 : 2045 7.
34. Mishkin D, Van Deinse W, Becker J et al. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 2006 12 : 827 8.
35. Vesga L, Terdiman J, Mahadevan U. Adalimumab use in pregnancy. Gut 2005 54 : 890.
36. Ferran M, Pujol R. Seguridad de adalimumab. Actas Dermosifiliogr 2008 99 (Suppl. 2 15 24.
37. Liao Y, Chiu H, Tseng Y et al. Comparison of cutaneous tolerance and efficacy of calcitriol 3 microg g(-1) ointment and tacrolimus 0.3 mg g(-1) ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007 157 : 1005 12.
38. Martín Ezquerra G, Sánchez Regaña M, Herrera Acosta E et al. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol 2006 5 : 334 6.
39. Gribetz C, Ling M, Lebwohl M et al. Pimecrolimus cream 1% in the treatment of intertriginous psoriasis: a double-blind, randomized study. J Am Acad Dermatol 2004 51 : 731 8.
40. Kreuter A, Sommer A, Hyun J et al. 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study. Arch Dermatol 2006 142 : 1138 43.
41. Lebwohl M, Freeman A, Chapman M et al. Tacrolimus Ointment Study Group. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol 2004 51 : 723 30.
42. Kroft E, Erceg A, Maimets K et al. Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol 2005 19 : 249 51.
43. Scheinfeld N. The use of topical tacrolimus and pimecrolimus to treat psoriasis: a review. Dermatol Online J 2004 10 : 3.
44. Brune A, Miller D, Lin P et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007 24 : 76 80. (Pubitemid 46245628)
45. Wollina U. The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. Am J Clin Dermatol 2007 8 : 157 73.
46. Alomar A, Corella F, Garcia-Navarro X. Tacrolimus en enfermedades diferentes a la dermatitis atópica. Actas Dermosifiliogr 2008 99 (Suppl. 2 26 35. (Pubitemid 351239788)
47. Christophers E. Comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2006 20 : 52 5.
48. Neimann AL, Shin DB, Wang X et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006 55 : 829 35.
49. Puig-Sanz L. La psoriasis, una enfermedad sistémica. Actas Dermosifiliogr 2007 98 : 396 402.
50. Gottlieb A, Matheson R, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 139 : 1627 32.
51. Mease P, Kivitz A, Burch F et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004 50 : 2264 72.
52. Boehncke WH, Brasie RA, Barker J et al. Recommendations for the use of etanercept in psoriasis: a European dermatology expert group consensus. J Eur Acad Dermatol Venereol 2006 20 : 988 98.
53. Jacobsson LT, Turesson C, Gulfe A et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005 32 : 1213 18.
54. Oranje A, Marcoux D, Svensson A et al. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol 1997 36 : 203 8.
55. Park S, Suh D, Youn J. A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol 1999 16 : 321 5.
56. Jain V, Aggarwal K, Jain K et al. Narrow-band UV-B phototherapy in childhood psoriasis. Int J Dermatol 2007 46 : 320 2.
57. Pasic A, Ceovic R, Lipozencic J et al. Phototherapy in pediatric patients. Pediatr Dermatol 2003 20 : 71 7.
58. Dubertret L, Mrowietz U, Ranki A et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006 155 : 729 36.
59. Owen C, Chalmers R, O'Sullivan T et al. A systematic review of antistreptococcal interventions for guttate and chronic plaque psoriasis. Br J Dermatol 2001 145 : 886 90.
60. Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002 146 : 351 64.
61. Mazzotta A, Esposito M, Carboni I et al. Clobetasol propionate foam 0.0n5% as a novel topical formulation for plaque-type and scalp psoriasis. J Dermatolog Treat 2007 18 : 84 7.
62. Saraceno R, Griffiths CE. A European perspective on the challenges of managing psoriasis. J Am Acad Dermatol 2006 54 : S81 4.
63. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005 152 : 861 7.
64. Heydendael V, Spuls P, Opmeer B et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 349 : 658 65.
65. Lowe NJ, Roenigk H, Voorhees JJ. Etretinate. Appropriate use in severe psoriasis. Arch Dermatol 1988 124 : 527 8.
66. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001 45 : 649 61.
67. Ho V. The use of ciclosporin in psoriasis: a clinical review. Br J Dermatol 2004 150 : 1 10. (Pubitemid 38903573)
68. Ling M. Acitretin: optimal dosing strategies. Am Acad Dermatol 1999 41 : S13 17.
69. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993 28 : 466 9.
70. Strober B, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005 53 : 652 9.
71. Chládek J, Simková M, Vanecková J et al. The effect of folic acid supplementation on the pharmacokinetics and pharmacodynamics of oral methotrexate during the remission-induction period of treatment for moderate-to-severe plaque psoriasis. Eur J Clin Pharmacol 2008 64 : 347 55.
72. Hoekstra M, Haagsma C, Neef C et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 2004 31 : 645 8.
73. Hamilton R, Kremer J. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Rheumatology 1997 36 : 86 90.
74. Weatherhead S, Robson S, Reynolds N. Management of psoriasis in pregnancy. Br Med J 2007 334 : 1218 20.
75. Opmeer B, Heydendael V, deBorgie C et al. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol 2007 60 : 696 703. (Pubitemid 46891754)
76. Marcil I, Stern R. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet 2001 358 : 1042 5.
77. Chalmers RJ, Kirby B, Smith A et al. Replacement of routine liver biopsy by procollagen III aminopeptide for monitoring patients with psoriasis receiving long-term methotrexate: a multicentre audit and health economic analysis. Br J Dermatol 2005 152 : 444 50.
78. Zachariae H, Heickendorff L, Søgaard H. The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up. Br J Dermatol 2001 144 : 100 3.
79. Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5 y cohort study. J Invest Dermatol 2003 120 : 211 16.
80. Saporito F, Menter M. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol 2004 50 : 301 9.
81. Papoutsaki M, Chimenti MS, Costanzo A et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. J Am Acad Dermatol 2007 57 : 269 75.
82. Zachariae H, Søgaard H, Heickendorff L. Serum aminoterminal propeptide of type III procollagen. A non-invasive test for liver fibrogenesis in methotrexate-treated psoriatics. Acta Derm Venerol 1989 69 : 241 4.
83. De Felice C, Mazzotta A, Esposito M et al. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. J Dermatol Treat 2006 17 : 355 8.
84. Zachariae C, Mørk N-J, Reunala T et al. The combination of Etanercept and Methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of Methotrexate therapy. Acta Derm Venereol 2008 88 : 495 501.
85. Mallbris L, Granath F, Hamsten A et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006 54 : 614 21.
86. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 97.
87. Sterry W, Barker J, Boehncke WH et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004 151 (Suppl 69 3 17. (Pubitemid 39215184)
88. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003 25 : 2487 505.
89. Gamo R, López-Estebaranz J. Terapia biológica y psoriasis. Actas Dermosifiliogr 2006 97 : 1 17.
90. Collins P, Rogers S. The efficacy of methotrexate in psoriasis - a review of 40 cases. Clin Exp Dermatol 1992 17 : 257 60.
91. Roenigk HJ, Auerbach R, Maibach H et al. Methotrexate in psoriasis: Consensus Conference. J Am Acad Dermatol 1988 38 : 478 85.
92. Weinstein G, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971 103 : 33 8.
93. Nast A, Kopp IB, Augustin M et al. Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007 5 (Suppl. 3 1 119. (Pubitemid 47033875)
94. Kuijpers A, Van de Kerkhof P. Risk-benefit assessment of methotrexate in the treatment of severe psoriasis. Am J Clinical Dermatol 2000 1 : 27 39.
95. Van Dooren-Greebe R, Kuijpers A, Mulder J et al. Methotrexate revisited: effects of long term treatment in psoriasis. Br J Dermatol 1994 130 : 201 10.
96. Antoniou C, Stefanaki I, Stratigos A et al. The Greek experience with efalizumab in psoriasis from a University Dermatologic Hospital. Br J Dermatol 2007 156 : 12 16. (Pubitemid 46434869)
97. Costanzo A, Peris K, Talamonti M et al. Long-term treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007 156 (Suppl 2 17 23. (Pubitemid 46434870)
98. Dubertret L, Sterry W, Bos JD et al. Clinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006 155 : 170 81.
99. Ferrandiz C, Carrascosa J. Managing moderate-to-severe psoriasis with efalizumab: experience at a single Spanish institute. Br J Dermatol 2007 156 : 24 9.
100. Gordon K, Papp K, Hamilton T et al. Efalizumab for patients with moderate to severe plaque psoriasis. A randomized controlled trial. JAMA 2003 290 : 3073 80.
101. Gottlieb A, Hamilton T, Caro I et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006 54 : S154 63.
102. Gottlieb A, Miller B, Lowe N et al. Subcutaneously administered efalizumab (anti-CD11a) improves signs and symptoms of moderate to severe plaque psoriasis. J Cutan Med Surg 2003 7 : 198 207. (Pubitemid 36859096)
103. Gupta A, Cherman A. Efalizumab in the treatment of psoriasis. J Cutan Med Surg 2006 10 : 57 68.
104. Hamilton T. Clinical considerations of efalizumab therapy in patients with psoriasis. Semin Cutan Med Surg 2005 24 : 19 27. (Pubitemid 40410095)
105. Kragballe K. Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark. Br J Dermatol 2007 156 (Suppl. 2 7 11. (Pubitemid 46434868)
106. Leonardi C, Papp K, Gordon K et al. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized Phase III trial. J Am Acad Dermatol 2005 52 : 425 33.
107. Menter A, Gordon K, Carey W et al. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005 141 : 31 8.
108. Menter A, Hamilton T, Toth D et al. Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study. Int J Dermatol 2007 46 : 637 48.
109. Menter A, Leonardi C, Sterry W et al. Long-term management of plaque psoriasis with continuous efalizumab therapy. J Am Acad Dermatol 2006 54 : S182 8.
110. Morse L, Yarbrough L, Hogan D. Cervical cancer in a woman associated with long-term efalizumab therapy. J Am Acad Dermatol 2005 53 : 354 5.
111. Papp K, Bissonnette R, Krueger J et al. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody. J Am Acad Dermatol 2001 45 : 665 74.
112. Selenko-Gebauer N, Karlhofer F, Stingl G. Efalizumab in routine use: a clinical experience. Br J Dermatol 2007 156 (Suppl. 2 1 6. (Pubitemid 46434867)
113. Vazquez-Veiga H, Seoane-Pose M, Fernandez-Blanco M. Mi experiencia clínica con efalizumab en el Hospital de Conxo. Actas Dermosifiliogr 2008 99 (Suppl. 1 62 9.
114. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005 366 : 1367 74.